Journal of the Formosan Medical Association
Volume 109, Issue 5 , Pages 362-368 , May 2010

Characteristics and Risk Factors of Oxaliplatin-related Hypersensitivity Reactions

  • Yu-Yun Shao

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • Department of Oncology, National Taiwan University Hospital Yun-Lin Branch, Yunlin, Taiwan
    • ,
  • Fu-Chang Hu

      Affiliations

    • Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Jin-Tung Liang

      Affiliations

    • Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Wen-Tzu Chiu

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Ann-Lii Cheng

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Chih-Hsin Yang

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr Chih-Hsin Yang, Department of Oncology, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 10002, Taiwan

Received 31 March 2009 ,Revised 16 August 2009 ,Accepted 25 August 2009.

References 

  1. de Gramont A , Vignoud J , Tournigand C , et al.   Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer . Eur J Cancer . 1997;33:214–219
  2. Thomas RR , Quinn MG , Schuler B , et al.   Hypersensitivity and idiosyncratic reactions to oxaliplatin . Cancer . 2003;97:2301–2307
  3. Andre T , Boni C , Mounedji-Boudiaf L , et al.   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer . N Engl J Med . 2004;350:2343–2351
  4. Brandi G , Pantaleo MA , Galli C , et al.   Hypersensitivity reactions related to oxaliplatin (OHP) . Br J Cancer . 2003;89:477–481
  5. Gowda A , Goel R , Berdzik J , et al.   Hypersensitivity reactions to oxaliplatin: incidence and management . Oncology (Williston Park) . 2004;18:1671–1684
  6. Kim BH , Bradley T , Tai J , et al.   Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review . Oncology . 2009;76:231–238
  7. Polyzos A , Tsavaris N , Gogas H , et al.   Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience . Oncology . 2009;76:36–41
  8. Shao YY , Hong RL . Fatal thrombocytopenia after oxaliplatin-based chemotherapy . Anticancer Res . 2008;28:3115–3117
  9. Stahl M , Koster W , Wilke H . Reaction after oxaliplatin-with corticosteroids? . Ann Oncol . 2001;12:874
  10. Siu SW , Chan RT , Au GK . Hypersensitivity reactions to ox-aliplatin: experience in a single institute . Ann Oncol . 2006;17:259–261
  11. Lenz G , Hacker UT , Kern W , et al.   Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution . Anticancer Drugs . 2003;14:731–733
  12. Lee MY , Yang MH , Liu JH , et al.   Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication . Support Care Cancer . 2007;15:89–93
  13. National Cancer Institute U.S.  . Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0 . Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm 2006; [Date accessed: Mar 1, 2009]
  14. de Vries RS , Mattijssen EJ , van Sorge AA . Serious delayed hypersensitivity reaction to oxaliplatin . Ann Oncol . 2006;17:1723–1724
  15. Saunders MP , Denton CP , O'Brien ME , et al.   Hypersensitivity reactions to cisplatin and carboplatin-a report on six cases . Ann Oncol . 1992;3:574–576
  16. Onoyama Y , Umezu T , Kuriaki Y , et al.   Hypersensitivity reactions to cisplatin following multiple uncomplicated courses: a report on two cases . J Obstet Gynaecol Res . 1997;23:347–352
  17. Khan A , Hill JM , Grater W , et al.   Atopic hypersensitivity to cis-dichlorodiammineplatinum(II) and other platinum complexes . Cancer Res . 1975;35:2766–2770
  18. Sliesoraitis S , Chikhale PJ . Carboplatin hypersensitivity . Int J Gynecol Cancer . 2005;15:13–18
  19. Meyer L , Zuberbier T , Worm M , et al.   Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule . J Clin Oncol . 2002;20:1146–1147
  20. Gammon D , Bhargava P , McCormick MJ . Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol . Oncologist . 2004;9:546–549
  21. Lim KH , Huang MJ , Lin HC , et al.   Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule . Anticancer Drugs . 2004;15:605–607
  22. Mis L , Fernando NH , Hurwitz HI , et al.   Successful desensitization to oxaliplatin . Ann Pharmacother . 2005;39:966–969
  23. Edmondson DA , Gruling BJ , Urmanski AM , et al.   Oxaliplatin hypersensitivity: case report and successful repeat desensitization . Am J Ther . 2007;14:116–118

PII: S0929-6646(10)60064-2

doi: 10.1016/S0929-6646(10)60064-2

Journal of the Formosan Medical Association
Volume 109, Issue 5 , Pages 362-368 , May 2010

Article Tools